CSCSL Limited CSLLY · OTC
$34.47 +0.19% (+$0.07)
- Market cap
- $130.1B
- Enterprise value
- $139.5B
- P/E
- -
- Forward P/E
- 43.3x
- PEG
- -
- P/S
- 8.3x
- P/FCF
- 45.2x
- EV/EBITDA
- 27.5x
- ROIC
- 10.0%
- Gross margin
- 47.7%
- Net margin
- -16.4%
- Dividend yield
- 2.16%
- Payout ratio
- -
- Net debt/EBITDA
- 1.8x
- Beta
- 0.08
- Free float
- 100.0%
About the company
CSL Limited is an Australian biotechnology company headquartered in Melbourne and one of the world’s leading developers and manufacturers of plasma-derived therapies, vaccines, and biotherapeutics. Founded in 1916 as a government laboratory, it now operates globally through its subsidiaries CSL Behring and CSL Seqirus. The company focuses on treating rare and serious conditions such as blood clotting disorders, immune deficiencies, respiratory diseases, and neurological disorders, while also being one of the largest producers of influenza vaccines worldwide. CSL emphasizes innovation, scientific research, and the advancement of biomedical technologies, with its products available in over 100 countries.
Sector
Healthcare
Industry
Biotechnology
CEO
Gordon Naylor DipCompSc
Employees
29,000
Headquarters
Melbourne
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number